18 Jun 2026 [162] Drug-induced peripheral edema: a common, overlooked, reversible harm

Jump to: Abstract | Full Text | Plain Language Summary | Key messages | Conclusions | Webinar | References

Plain Language Summary

Swelling caused by medicines: what you need to know?

What is peripheral edema?

Peripheral edema is swelling in the body, usually in the feet, ankles or legs, sometimes in the face or abdomen. It happens when extra fluid gets trapped in your body’s tissues. While it can be a sign of a health condition like heart failure, it is very often just a side effect of a medicine you are taking.

Which medicines are known to cause this swelling?

Several common drugs can cause fluid to build up. The most frequent medicines include:

• Blood pressure pills: medicines such as amlodipine or nifedipine. About 1 in 10 older people develop swelling within a year of starting to take these drugs.
• Nerve pain or seizure medications: drugs like gabapentin or pregabalin cause swelling in about 1 in 20 patients.
• Over-the-counter pain relievers: common NSAIDs (like ibuprofen or naproxen) can increase the risk of leg swelling, especially in older people.
• Other drugs: certain mental health medicines (psychotropics), Parkinson’s drugs, and hormone replacement medicines.

Why does my medication cause swelling?

It usually happens in 1 of 2 ways. Some drugs cause your blood vessels to widen (vasodilation), which allows fluid to leak into the surrounding tissues. Other drugs, like everyday pain relievers, cause your body to hold onto extra salt (sodium retention), which traps water in your system.

Can I just take a ‘water pill’ (diuretic) to fix it?

No, not usually. If the swelling is caused by blood vessels getting wider (from blood pressure or nerve pain pills), water pills will not work. The best solution is safely lowering the dose, stopping, or changing the medicine that caused the problem in the first place.

What should my doctor and I do if my legs start swelling?

If you notice new or worse swelling, you and your doctor should follow these steps before rushing into more medical tests:

1. Check all your medicines: look at everything you take, including new prescriptions, recent dose increases, and over-the-counter pain pills.
2. Find the trigger drug: check if any of your medicines match the list of drugs known to cause swelling.
3. Try a safe change: if it is safe, your doctor may have you briefly stop, lower, or change the suspected drug to see if the swelling goes away.
4. Talk about your goals: decide together if the swelling bothers you enough to change a medicine that might otherwise be helping you.
5. Use daily comfort actions: raising your legs up on pillows or wear compression stockings can help reduce the swelling, but they should be used alongside fixing the medicine problem, not instead of it.

What is the main takeaway message?

Swelling from medicines is common, often overlooked, and can usually be fixed. If you take several medicines and notice new swelling, always ask your doctor to check your medications list first. Adjusting the drug you are already taking is much better than adding a new medicine to treat a side effect.

Drug-induced peripheral edema: a common, overlooked, reversible harm

Abstract

Background: Drug-induced peripheral edema is a common, under-recognized, and usually reversible adverse event. Up to 10 percent of older adults taking amlodipine or nifedipine and up to 5 percent using gabapentin or pregabalin develop peripheral edema within a year of starting treatment. Non-steroidal anti-inflammatory drugs (NSAIDs) double the rate of edema through sodium retention. Because vasodilation-induced edema does not respond to diuretics, misdiagnosis may lead to prescribing cascades or unnecessary diagnostic investigations for conditions like heart failure.

Aims: This Therapeutics Letter aims to guide clinicians in identifying medication-related harms of new or worsening peripheral edema, differentiating between physiological mechanisms (vasodilation versus sodium retention), and prioritizing deprescribing strategies over active pharmacological management.

Recommendations: Clinicians evaluating new-onset peripheral edema should execute a five-step strategy alongside standard diagnostic protocols:

1. Conduct a careful medication review targeting recent prescription changes and over-the-counter drugs such as NSAIDs.
2. Identify drugs associated with edema, including dihydropyridine calcium channel blockers, gabapentinoids, psychotropics, NSAIDS, and hormonal therapies.
3. If safe to do so, briefly stop, reduce, or switch the suspected culprit drug before considering new treatments.
4. Align clinical decisions with patient goals of care to determine if edema severity outweighs the therapeutic benefit of the medication.
5. Employ symptom-focussed measures, such as compression stockings and leg elevation as non-pharmacological adjuncts rather than substitutes for addressing the underlying cause.

Conclusions: Medication side effects should be the main consideration in cases of new-onset peripheral edema, particularly in patients with polypharmacy. Deprescribing or modifying the offending drug is preferable to adding medications or diagnostic interventions.

Drug-induced peripheral edema: a common, overlooked, reversible harm

Vignette: A 69-year-old woman presents with swollen ankles at your walk-in clinic. Her family physician just retired. What will you ask her?

Key messages

• When a patient presents with new or worsening peripheral edema, ask if they started a new medication in the last few days to months.
• If they started amlodipine, nifedipine, gabapentin, or pregabalin, briefly stop, reduce, or switch the medication before, or in concert with, ordering investigations for other illnesses, like heart failure.
• About 1 in 10 seniors develop peripheral edema within a year of starting amlodipine or nifedipine. About half as many do so after gabapentin or pregabalin. Their mechanism—vasodilation—does not respond to diuretics. Some psychotropics, dopaminergics, and hormone therapies also increase rates of edema by vasodilation. 
• NSAIDs double the rate of peripheral edema. The mechanism—sodium retention—usually responds to a diuretic, but deprescribing is most effective, if appropriate.

Edema is common and problematic

Peripheral edema—typically bilateral, pitting swelling of the lower limbs—is common and distressing. Acute edema (<3 months), if untreated, can lead to chronic edema. One estimate is that 1.25 million Canadians live with chronic edema, the vast majority peripheral edema.¹ Chronic edema (now included under the term “lymphedema”²) is at least twice as common in those with obesity, pain, sedentary lifestyle, mobility limitations, or those aged over 80 (compared to those aged 51-59).³

Chronic (mostly peripheral) edema reduces quality of life through pain, reduced mobility, and altered appearance, and is associated with mood disorders.⁴ Delayed wound healing, skin breakdown, cellulitis, and venous ulcers can occur and lead to more complications. A UK study found 29% of people with chronic edema reported a related acute infection in the previous year, of which one quarter required hospitalization for IV antibiotics, staying an average of 12 days.⁵

Pathophysiology

Peripheral edema (hereafter “edema” for short) results from excess fluid accumulation in the interstitial space, when capillary filtration exceeds capacity for lymphatic drainage. Medications can contribute to this via the same mechanisms as disease:^6,7

1. Increased capillary hydrostatic pressure (vasodilation): Pre-capillary arteriolar dilation, without compensatory venous dilation, increases hydrostatic pressure within capillary beds, promoting fluid movement into the interstitial space. Total body sodium and water are usually unchanged.
2. Sodium and water retention: Impaired renal sodium excretion leads to osmotic retention of water, resulting in true intravascular volume expansion.
3. Increased capillary permeability: Damage to or dysfunction of the vascular endothelium allows proteins and fluid to leak into tissues.
4. Lymphatic dysfunction: Impaired lymphatic drainage prevents removal of interstitial fluid and proteins, resulting in persistent and/or asymmetric edema.

Drug-related edema is usually bilateral, in the lower extremities, pitting, and without skin colour change, though erythema (e.g., pemetrexed) or non-blanching petechial rash (e.g., pigmented purpuric dermatosis from calcium channel blockers (CCBs)) may occur.^6,8

Many common drugs are associated with peripheral edema

With almost all drugs that cause edema (Table), the effect is dose-dependent, edema can develop weeks to months after initiation or dose escalation and often resolves within days to 2 weeks of discontinuation.⁶

Risk factors for drug-induced peripheral edema include diabetes, female sex, older age, and polypharmacy.^6,9 Exception: seniors are less susceptible to edema from psychiatric medications, possibly due to reduced histamine-related responses.^6,10

Drug-related edema may result in overdiagnosis, prescribing cascades

Prescribing cascades result from adding a drug to treat drug-induced edema, whether recognized as such or mislabeled as a new or worsening medical condition.^11,12 For example, edema resulting from vasodilation triggered by pregabalin or gabapentin, can mistakenly be seen as impaired cardiac contractility leading to suspicion of heart failure.¹³

Seniors on CCBs are twice as likely to be put on a diuretic than those given a different class of medicine for their hypertension.¹⁴ Likewise, older adult Canadians started on gabapentin or pregabalin were 1.44 times more likely to be put on a loop diuretic prescription than those not prescribed these drugs, with the effect being more pronounced at higher doses.¹⁵

Diuretic harm

Diuretics expose patients—particularly seniors—to electrolyte disturbances, hypotension, confusion, falls, and hospitalization.^16,17 Therefore, in CCB-related vasodilatory edema, diuretics are not sensible: they may slightly reduce edema but at the cost of volume depletion and net harm.¹⁸ Safer strategies are to reduce or replace the CCB.¹⁸ There is no evidence supporting diuretics for lymphedema or chronic venous insufficiency.^19,20

Table: Common drugs that can cause peripheral edema, grouped by main mechanism

Five steps

When a patient presents with new peripheral edema, consider whether new edema could be caused by a drug, alongside other etiologies.²⁸

1. Review the medication list carefully, including recent additions, dose increases, and over-the-counter drugs (e.g., NSAIDs).
2. Identify drugs known to cause edema, (e.g., dihydropyridine CCBs, gabapentinoids, psychotropics, NSAIDs, and hormonal therapies).
3. Briefly stop, reduce, or switch the most likely culprit if safe to do so, and reassess symptoms at next visit before ordering investigations or adding treatments.
4. Ask patient if the improvement in symptoms is worth giving up the benefits of the medication, taking into account patient goals of care. Some patients find edema intolerable, while others are not bothered.
5. Use symptom-focused measures (e.g., leg elevation, compression stockings) as adjuncts, not substitutes for addressing the underlying cause.

Conclusions

Drug-induced peripheral edema is common, under-recognized, and usually reversible. Medications should be reviewed first in new-onset edema, especially in patients with polypharmacy. Stopping, reducing, or switching the offending drug is preferable to adding another medication.

Vignette resolution: The patient has no symptoms other than edema, but you discover she started gabapentin for sciatica 6 months ago and recently increased the dose. Examination reveals bilateral pitting edema with normal skin, normal heart sounds and JVP and HJR, clear lungs, and no signs of liver failure. You advise reducing the dose of gabapentin to <1800 mg/day, and her edema improves markedly within 2 weeks. She decides not to proceed with the bloodwork (BNP, electrolytes, creatinine, liver function tests, and TSH) that you had recommended in case her edema did not improve.

The Therapeutics Letter is a member of the International Society of Drug Bulletins (ISDB), a world-wide network of independent drug bulletins that aims to promote international exchange of quality information on drugs and therapeutics.

Webinar

The Therapeutics Initiative included a presentation by Dr. Jessica Otte on this topic in the 2025 Annual Drug Therapy Course in November 28-29, 2025. Back by popular demand, the Therapeutics Initiative hosted an encore 1-hour webinar on Wednesday, June 24th, 2026 at 12:00 PM PDT. In this TI Best Evidence Webinar, Dr. Otte explored the problem of edema with a focus on its iatrogenic causes, reviewed the mechanisms by which medications lead to fluid accumulation, highlighting how an understanding of these pathways can guide management. Practical strategies for treatment were also be discussed. The recording of this webinar will be posted here and in the TI YouTube channel soon.

References

1. 1. Keast D, Towers A, Letellier ME, Damji A. The prevalence of lymphedema in Canada: an update. Accurate determinations of prevalence remain a challenge. Pathways. 2025; 14(1): 5-8. DOI: 10.70472/CDPU5571
   2. Keast DH, Moffatt C, Janmohammad A. Lymphedema Impact and Prevalence International Study: The Canadian Data. Lymphatic Research & Biology. 2019; 17(2):178-186. DOI: 10.1089/lrb.2019.0014
   3. Besharat S, Grol-Prokopczyk H, Gao S, et al. Peripheral edema: A common and persistent health problem for older Americans. PLoS One. 2021; 16(12):e0260742. DOI: 10.1371/journal.pone.0260742
   4. Mercier G, Pastor J, Moffatt C, et al. LIMPRINT: Health-Related Quality of Life in Adult Patients with Chronic Edema. Lymphatic Research & Biology. 2019; 17(2):163-167. DOI: 10.1089/lrb.2018.0084
   5. Moffatt CJ, Franks PJ, Doherty DC, et al. Lymphoedema: an underestimated health problem. QJM. 2003; 96(10):731-738. DOI: 10.1093/qjmed/hcg126
   6. Largeau B, Cracowski JL, Lengelle C, et al. Drug-induced peripheral oedema: An aetiology-based review. British Journal of Clinical Pharmacology. 2021; 87(8):3043–3055. DOI: 10.1111/bcp.14752
   7. Acosta F, Godoy A, Tabares A. Advances in understanding medication-induced lower limb edema: Review for clinical practice. Canadian Journal of General Internal Medicine. 2024; 19(4):207–220. DOI: 10.3138/cjgim.2024.0005
   8. Schetz D, Kocić I. A new adverse drug reaction–Schamberg’s disease caused by amlodipine administration–a case report. British Journal of Clinical Pharmacology. 2015; 80(6):1477-1478. DOI: 10.1111/bcp.12742
   9. Hayes KN, Belanger E, Oganisian A, et al. Predictors of a Gabapentinoid-Loop-Diuretic Prescribing Cascade in U.S. Nursing Home Residents. Journal of the American Geriatric Society. 2026; 74(2):336-344. DOI: 10.1111/jgs.70219
   10. Engel J, Haack B, Zolk O, et al. Edema related to treatment with psychotropic drugs. J Neural Transm. 2024; 131(3):253-266. DOI: 10.1007/s00702-024-02738-6
   11. Therapeutics Initiative. Reducing prescribing cascades. Therapeutics Letter. 2022; 138. https://ti.ubc.ca/letter138
   12. Carollo M, Crisafulli S, Zerio M, et al. Prescribing Cascades: An Umbrella Review and Updated Systematic Review. Drugs & Aging. 2026; 43(5):397-424. DOI: 10.1007/s40266-026-01295-9
   13. Largeau B, Bordy R, Pasqualin C, et al. Gabapentinoid-induced peripheral edema and acute heart failure: A translational study combining pharmacovigilance data and in vitro animal experiments. Biomedicine & Pharmacotherapy. 2022; 149:112807. DOI: 10.1016/j.biopha.2022.112807
   14. Savage RD, Visentin JD, Bronskill SE, et al. Evaluation of a Common Prescribing Cascade of Calcium Channel Blockers and Diuretics in Older Adults With Hypertension. JAMA Intern Med. 2020; 180(5):643–651. DOI: 10.1001/jamainternmed.2019.7087
   15. Read SH, Giannakeas V, Pop P, et al. Evidence of a gabapentinoid and diuretic prescribing cascade among older adults with lower back pain. Journal of the American Geriatrics Society. 2021; 69(10):2842-2850. DOI: 10.1111/jgs.17312
   16. Cosgrave N, Frydenlund J, Beirne F, et al. Hospital admissions due to adverse drug reactions and adverse drug events in older adults: a systematic review. Age & Ageing. 2025; 54(8):afaf231. DOI: 10.1093/ageing/afaf231
   17. MacClennan W. Diuretics in the elderly: how safe? BMJ. 1988; 296(6636):1551-1552. DOI: 10.1136/bmj.296.6636.1551
   18. Sica DA. Calcium channel blocker-related peripheral edema: can it be resolved? J Clin Hypertens. 2003; 5(4):291-295. DOI: 10.1111/j.1524-6175.2003.02402.x
   19. Patel H, Skok C, DeMarco A. Peripheral Edema: Evaluation and Management in Primary Care. Am Fam Physician. 2022; 106(5):557-564. PMID: 36379502
   20. Keast DH, Despatis M, Allen JO, Brassard A. Chronic oedema/lymphoedema: under-recognised and under-treated. International Wound Journal. 2015; 12(3):328-333. DOI: 10.1111/iwj.12224
   21. Makani H, Bangalore S, Romero J, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate–a meta-analysis of randomized trials. J Hypertens. 2011; 29(7):1270-80. DOI: 10.1097/HJH.0b013e3283472643
   22. Liang L, Kung JY, Mitchelmore B, et al. Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: A systematic review and network meta-analysis. Journal of Clinical Hypertension. 2022; 24(5):536-554. DOI: 10.1111/jch.14436
   23. Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Current Cardiology Reports. 2002; 4(6):479-482. DOI: 10.1007/s11886-002-0110-9
   24. Finegan A, Mabrouk U, Nelson LA. Gabapentin-induced bilateral lower extremity edema in a patient with pervasive developmental disorder and schizoaffective disorder. Ment Health Clin. 2020; 10(4):250-253. DOI: 10.9740/mhc.2020.07.250
   25. Therapeutics Initiative. Finding the lowest effective dose for non-opioid analgesics. Therapeutics Letter. 2021; 134. https://ti.ubc.ca/letter134
   26. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. Journal of Clinical Pharmacology. 1991; 31(7):588-598. DOI: 10.1002/j.1552-4604.1991.tb03743.x
   27. Gardner-Nix J. Opioids Causing Peripheral Edema. Journal of Pain and Symptom Management. 2002; 23(6):453–455. DOI: 10.1016/S0885-3924(02)00404-9
   28. Canada’s Drug Agency. 5 Tips to Manage Polypharmacy. https://www.cda-amc.ca/sites/default/files/corporate/corp_committees/Expert_Panel-Appropriate_Use/5_Tips_Manage_Polypharmacy_Toolkit_EN.pdf